All Roche articles
-
-
BusinessTrump coaxes big promises from big pharma
Several drug industry giants are now pledging to freeze price increases in the US, but some suggest the movement is a publicity stunt or worse
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessRoche offloads majority of rights to lebrikizumab
Deal with Dermira could be worth well over $1 billion
-
BusinessIndia probes Roche over biosimilars
Mylan and Biocon claim Roche abused its market dominance to quash generic breast cancer antibodies
-
BusinessFDA urges labs to test all blood donations for Zika
Agency has also given emergency authorisation to two new Zika blood tests
-
BusinessRoche sketches out Blueprint collaboration
Drug discovery startup will contribute to cancer immunotherapy projects aimed at kinase enzymes
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
BusinessRoche chases bolt-on acquisitions as it pushes into genomics
Company’s recent shopping spree aims to harness genome sequencing to advance personalised treatments
-
-
Business
Ranbaxy sues over withdrawn US approvals
Company says decision is ‘unconstitutional’ and deprives it of hundreds of millions of dollars in revenue
-
BusinessCHF3bn redevelopment for Roche’s Basel site
New buildings will move employees out of rented office space
-
BusinessRoche to buy InterMune for respiratory boost
$8.3bn deal gives Roche a leading position in pulmonary fibrosis
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
Business
Genentech to buy breast cancer specialist Seragon
$1.7bn deal for hormone receptor-destroying drug pipeline
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
BusinessRoche disputes unethical East German trial claims
Internal investigation concludes that 1980s trials were legally run and patients gave proper consent
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels